Long-term Outcome of Short-course High-dose Glucocorticoids for Severe Acute Respiratory Syndrome (SARS): A 17-Year Follow-up in SARS Survivors | Zendy

ChorWing Sing | Zendy; Kathryn Choon Beng Tan | Zendy; Ian Chi Kei Wong | Zendy; Bernard M.Y. Cheung | Zendy; ChingLung Cheung | Zendy

Open Access

Long-term Outcome of Short-course High-dose Glucocorticoids for Severe Acute Respiratory Syndrome (SARS): A 17-Year Follow-up in SARS Survivors

Author(s) -

ChorWing Sing,

Kathryn Choon Beng Tan,

Ian Chi Kei Wong,

Bernard M.Y. Cheung,

ChingLung Cheung

Publication year - 2020

Publication title -

clinical infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.44

H-Index - 336

eISSN - 1537-6591

pISSN - 1058-4838

DOI - 10.1093/cid/ciaa992

Subject(s) - medicine , severe acute respiratory syndrome , respiratory system , glucocorticoid , covid-19 , respiratory disease , pediatrics , disease , lung , infectious disease (medical specialty)

Use of high-dose glucocorticoids for COVID-19 (caused by SARS-CoV-2) is controversial because of safety concerns. We examined the long-term consequences of glucocorticoid use in severe acute respiratory syndrome (caused by SARS-CoV-1) survivors. Results showed that high-dose glucocorticoids greatly increased the long-term risk of avascular necrosis but not other major diseases.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research